-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] People need to take medicine when they are sick, but for some patients, especially those with chronic diseases, the cost of taking medicine for a long time is a lot of expenses
.
In recent years, with the advancement of new medical reform policies such as centralized procurement and medical insurance, a large number of high-quality and low-cost drugs have been included, and the prices have been greatly reduced, effectively reducing the burden of drug costs for patients
.
Cardiovascular and cerebrovascular disease is a common disease that seriously threatens the health of human beings, especially the middle-aged and elderly people over 50 years old, with a large number of patients
.
According to the "China Cardiovascular Disease Report 2018" released by the National Cardiovascular Disease Center, the number of patients with cardiovascular and cerebrovascular diseases in China is as high as nearly 300 million
.
Such patients require lifelong treatment and management, have a huge demand for related drugs, and carry a heavy burden of disease
.
The price reduction of cardiovascular and cerebrovascular drugs has attracted the attention of the majority of patients
.
In order to more effectively promote the standardized management of chronic diseases such as cardiovascular and cerebrovascular diseases and reduce the economic burden of the disease, relevant departments and related pharmaceutical companies have taken a series of measures in recent years.
There is no shortage of imported drugs
.
For example, in the 4+7 expanded scope of centralized procurement, Sanofi's classic antihypertensive drug irbesartan and hydrochlorothiazide tablets in the field of chronic diseases 150mg+12.
5mg in 7 pieces, the winning bid price in the centralized procurement expansion was adjusted to 7.
6 yuan, a drop of about 60%.
The selected regions include Guizhou, Hainan, Shandong, Hubei, Xinjiang (including the Corps), Sichuan, Shanxi, and Heilongjiang
.
Patients with cerebrovascular diseases in relevant areas can use these two classic original research drugs at reduced prices in hospitals, chain pharmacies and other channels to reduce the burden of drug costs
.
In addition to the price reduction of imported drugs, 2 domestic enterprises of irbesartan and hydrochlorothiazide tablets have also been selected, namely: Nanjing Zhengda Tianqing's 14-piece product, the winning price per box is 14.
28 yuan, and the winning areas include Gansu, Qinghai, Tibet, Zhejiang , Anhui, Henan, Jiangxi, Shaanxi, Liaoning; Zhejiang Huahai Pharmaceutical's 14-piece product, the winning price was 14.
67 yuan, and the winning areas included Jilin, Ningxia, Jiangsu, Guangdong, Guangxi, Yunnan, Hunan, and Inner Mongolia
.
Sanofi's anti-platelet drug Plavix (Clopidogrel) also successfully won the bid in the expansion of centralized procurement.
The price of 7-piece 75mg product has dropped from the original hundreds of yuan to 17.
81 yuan, a drop of as much as 70%
.
Ningxia, Shandong, Guangdong, Hunan, Jiangxi, Shanxi, Inner Mongolia and Guizhou were selected as the winning bidders for the drug
.
Bristol-Myers Squibb's antihypertensive drug Fosinopril Sodium Tablets was also selected in the expansion of centralized procurement.
The price of the 10mg 14-piece product was adjusted to 11.
8 yuan.
The selected regions included Shanxi, Yunnan, Qinghai, Guangdong, Hubei, Liaoning, Jiangsu, Hainan, Ningxia, Jilin, Inner Mongolia, Guizhou
.
In addition, in the fourth batch of national procurement of drugs, cardiovascular and cerebrovascular drugs such as Valsartan Amlodipine Tablets and Valsartan Hydrochlorothiazide Tablets were also successfully selected
.
Among them, Jiangsu Hengrui's 7-piece Valsartan Amlodipine Tablets won the bid price of 9.
72 yuan; Huayuan Pharmaceutical's 30-piece product, won the bid price of 82.
88 yuan
.
The companies selected for valsartan and hydrochlorothiazide tablets are: China Resources Secco Pharmaceuticals in 14-tablet packs, with a winning price of 25.
2 yuan per box; Beijing Biopharmaceuticals in 14-tablet varieties, with a winning price of 27.
02 yuan per box
.
At present, the national procurement of medicines has reached the sixth round (insulin) special project, and the seventh round of centralized procurement is also progressing
.
Judging from the results of the first five rounds of centralized collection, there are not a few products selected for cardiovascular and cerebrovascular drugs
.
According to incomplete statistics in the industry, only in terms of hypertension treatment drugs, 19 varieties of drugs won the bid in the first 5 rounds of centralized procurement, and there are many drugs that have dropped again and again
.
In general, with the normalization of centralized procurement, it is believed that more drugs will be included in the catalog with price reductions, which will be a great boon for the majority of cardiovascular and cerebrovascular patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, with the advancement of new medical reform policies such as centralized procurement and medical insurance, a large number of high-quality and low-cost drugs have been included, and the prices have been greatly reduced, effectively reducing the burden of drug costs for patients
.
Cardiovascular and cerebrovascular disease is a common disease that seriously threatens the health of human beings, especially the middle-aged and elderly people over 50 years old, with a large number of patients
.
According to the "China Cardiovascular Disease Report 2018" released by the National Cardiovascular Disease Center, the number of patients with cardiovascular and cerebrovascular diseases in China is as high as nearly 300 million
.
Such patients require lifelong treatment and management, have a huge demand for related drugs, and carry a heavy burden of disease
.
The price reduction of cardiovascular and cerebrovascular drugs has attracted the attention of the majority of patients
.
In order to more effectively promote the standardized management of chronic diseases such as cardiovascular and cerebrovascular diseases and reduce the economic burden of the disease, relevant departments and related pharmaceutical companies have taken a series of measures in recent years.
There is no shortage of imported drugs
.
For example, in the 4+7 expanded scope of centralized procurement, Sanofi's classic antihypertensive drug irbesartan and hydrochlorothiazide tablets in the field of chronic diseases 150mg+12.
5mg in 7 pieces, the winning bid price in the centralized procurement expansion was adjusted to 7.
6 yuan, a drop of about 60%.
The selected regions include Guizhou, Hainan, Shandong, Hubei, Xinjiang (including the Corps), Sichuan, Shanxi, and Heilongjiang
.
Patients with cerebrovascular diseases in relevant areas can use these two classic original research drugs at reduced prices in hospitals, chain pharmacies and other channels to reduce the burden of drug costs
.
In addition to the price reduction of imported drugs, 2 domestic enterprises of irbesartan and hydrochlorothiazide tablets have also been selected, namely: Nanjing Zhengda Tianqing's 14-piece product, the winning price per box is 14.
28 yuan, and the winning areas include Gansu, Qinghai, Tibet, Zhejiang , Anhui, Henan, Jiangxi, Shaanxi, Liaoning; Zhejiang Huahai Pharmaceutical's 14-piece product, the winning price was 14.
67 yuan, and the winning areas included Jilin, Ningxia, Jiangsu, Guangdong, Guangxi, Yunnan, Hunan, and Inner Mongolia
.
Sanofi's anti-platelet drug Plavix (Clopidogrel) also successfully won the bid in the expansion of centralized procurement.
The price of 7-piece 75mg product has dropped from the original hundreds of yuan to 17.
81 yuan, a drop of as much as 70%
.
Ningxia, Shandong, Guangdong, Hunan, Jiangxi, Shanxi, Inner Mongolia and Guizhou were selected as the winning bidders for the drug
.
Bristol-Myers Squibb's antihypertensive drug Fosinopril Sodium Tablets was also selected in the expansion of centralized procurement.
The price of the 10mg 14-piece product was adjusted to 11.
8 yuan.
The selected regions included Shanxi, Yunnan, Qinghai, Guangdong, Hubei, Liaoning, Jiangsu, Hainan, Ningxia, Jilin, Inner Mongolia, Guizhou
.
In addition, in the fourth batch of national procurement of drugs, cardiovascular and cerebrovascular drugs such as Valsartan Amlodipine Tablets and Valsartan Hydrochlorothiazide Tablets were also successfully selected
.
Among them, Jiangsu Hengrui's 7-piece Valsartan Amlodipine Tablets won the bid price of 9.
72 yuan; Huayuan Pharmaceutical's 30-piece product, won the bid price of 82.
88 yuan
.
The companies selected for valsartan and hydrochlorothiazide tablets are: China Resources Secco Pharmaceuticals in 14-tablet packs, with a winning price of 25.
2 yuan per box; Beijing Biopharmaceuticals in 14-tablet varieties, with a winning price of 27.
02 yuan per box
.
At present, the national procurement of medicines has reached the sixth round (insulin) special project, and the seventh round of centralized procurement is also progressing
.
Judging from the results of the first five rounds of centralized collection, there are not a few products selected for cardiovascular and cerebrovascular drugs
.
According to incomplete statistics in the industry, only in terms of hypertension treatment drugs, 19 varieties of drugs won the bid in the first 5 rounds of centralized procurement, and there are many drugs that have dropped again and again
.
In general, with the normalization of centralized procurement, it is believed that more drugs will be included in the catalog with price reductions, which will be a great boon for the majority of cardiovascular and cerebrovascular patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
